After a recent comment on the cost of GLP-1 weight-loss drugs, it appears Trumps’ populism is ramping up to cause problems for Big Pharma.
About The Podcast:
Millions of Americans feel confused and frustrated in their search for quality healthcare coverage.
Between out-of-control costs, countless inefficiencies, a lack of affordable universal access, and little focus on wellness and prevention, the system is clearly in dire need of change.
Hosted by healthcare policy and technology expert Marc S. Ryan, the Healthcare Labyrinth Podcast offers accessible, incisive deep dives on the most pressing issues and events in American healthcare.
Marc seeks to help Americans become wiser consumers and navigate the healthcare maze with more confidence and certainty through The Healthcare Labyrinth website and his book of the same name.
Marc is an unconventional Republican who believes that affordable universal access is a wise and prudent investment. He recommends common-sense solutions to reform American healthcare.
Tune in every week as Marc examines the latest developments in the space, offering analysis, insights, and predictions on the changing state of healthcare in America.
About The Episode:
On this episode, Marc discusses Donald Trump’s recent comments on the high cost of GLP-1 weight-loss drugs. His populist views could spell trouble for Big Pharma and he would be right to pursue further drug price reforms.
Key Takeaways:
While Donald Trump has been inconsistent on drug price reform, two recent developments show he may pursue serious changes.
His CMS says it will continue with Medicare drug price negotiations.
In an interview Trump bemoaned the high prices of GLP-1 weight-loss drugs.
He noted that such drugs are at least ten times more in the U.S. compared with other developed countries. He thinks this is inequitable and needs to change.
His comments are a significant development and tie into Trump’s views that other nations are taking Americans for a ride.
His populism could spell trouble for Big Pharma and signals a change for a Republican.
The drug market is not a free market and prices should be reformed.
All drug makers take advantage of the American public, but this is especially true of foreign firms – more than half of the top 50 drug makers.
Americans’ life expectancy is lower and health is poorer in part due to the disparities in drug prices.
As well, Americans essentially subsidize other developed countries’ healthcare systems through high American drug prices.
Trump should seize the initiative on drug price reform and make it part of his Make America Healthy Again agenda.
Connect with Marc
Resources
The Healthcare Labyrinth: A Guide to Navigating Health Plans and Fixing American Health Insurance
